PTCT
NASDAQPTC Therapeutics Inc.
Price$73.42+0.85 (+1.17%)
01:30 PM07:45 PM
News · 26 weeks66-50%
2026-03-012026-08-23
Mix3390d
- Insider16(48%)
- SEC Filings7(21%)
- Other4(12%)
- Earnings3(9%)
- Analyst2(6%)
- Leadership1(3%)
Latest news
25 items- PRPTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile– 17 abstracts and presentations planned at SSIEM Symposium –– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clin
- INSIDERDirector Schmertzler Michael sold $1,805,411 worth of shares (25,000 units at $72.22) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 2,813 shares at a strike of $25.69 and sold $204,127 worth of shares (2,813 units at $72.57) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile –– BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 –– PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $705,722 worth of shares (10,292 units at $68.57), decreasing direct ownership by 3% to 383,868 units (SEC Form 4) to cover taxes4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Sollie-Zetlmayer Hege Elisabeth was granted 6,000 shares, increasing direct ownership by 13% to 52,526 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERNew insider Sollie-Zetlmayer Hege Elisabeth claimed ownership of 46,526 shares (SEC Form 3)3 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECSEC Form 10-Q filed by PTC Therapeutics Inc.10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million –– Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 –WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026. "Our teams delivered another strong quarter enabling us to again raise 2026 product r
- PRHamilton Lane Board Elects Michael Schmertzler as New Independent DirectorCONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (NASDAQ:HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026. Schmertzler's appointment constitutes the fifth independent director to be named to the Board, serving alongside the firm's three executive directors. Hartley Rogers, Executive Co-Chairman at Hamilton Lane and Chairman of the HLNE Board, commented: "Michael is a highly accomplished executive who will be a strong addition to the Board. As the global investment landscape has become increasingly complex, his deep business, governance, technology and
- INSIDERCHIEF FINANCIAL OFFICER Gravier Pierre sold $280,743 worth of shares (3,494 units at $80.35), decreasing direct ownership by 4% to 83,986 units (SEC Form 4) to satisfy withholding obligation4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.About PTC Therapeutics, I
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 2,464 shares at a strike of $46.54 and sold $222,376 worth of shares (2,464 units at $90.25) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Smith Mary L. exercised 15,834 shares at a strike of $42.95 and sold $1,425,060 worth of shares (15,834 units at $90.00) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 46,774 shares at a strike of $38.86 and sold $4,093,482 worth of shares (46,774 units at $87.52) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott sold $432,118 worth of shares (5,079 units at $85.08) as part of a pre-agreed trading plan and exercised 5,079 shares at a strike of $43.36 (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 8,130 shares at a strike of $38.10 and sold $693,151 worth of shares (8,130 units at $85.26) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 26,283 shares at a strike of $38.11 and sold $2,254,463 worth of shares (26,283 units at $85.78) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 23,749 shares at a strike of $25.69 and sold $1,921,378 worth of shares (23,749 units at $80.90) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 10,522 shares at a strike of $46.54 and sold $822,868 worth of shares (10,462 units at $78.65) as part of a pre-agreed trading plan, increasing direct ownership by 0.06% to 105,272 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSVP, CHIEF ACCOUNTING OFFICER Utter Christine Marie exercised 19,686 shares at a strike of $25.69 and sold $1,487,474 worth of shares (19,686 units at $75.56) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company
PTCT FAQ
7 questionsWhat does PTC Therapeutics Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States...Where does PTCT stock trade?
PTC Therapeutics Inc. (PTCT) is listed on NASDAQ.What sector and industry is PTCT in?
PTC Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PTC Therapeutics Inc. go public?
PTC Therapeutics Inc. (PTCT) completed its IPO in 2013.What are analysts saying about PTCT?
PTC Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-09.What companies are similar to PTCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PTCT side-by-side with any of them on Quantisnow.How can I track PTCT on Quantisnow?
Quantisnow aggregates PTC Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTCT to receive live email and push alerts on every new disclosure.